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Background: Hepatocellular carcinoma (HCC) is a severe health condition associated with 
high hospitalizations and mortality rates, which also imposes a relevant economic burden.
Purpose: The aim of the present survey is to investigate treatment strategies and related costs 
for HCC in the intermediate and advanced stages of the disease.
Patients and methods: The survey was conducted in four Italian centers through structured 
interviews with physicians. Information regarding the stage of disease, treatments performed, 
and related health care resource consumption was included in the questionnaire. Direct health 
care cost per patient associated with the most relevant treatments such as sorafenib, transarterial 
chemoembolization (TACE), and transarterial radioembolization (TARE) was evaluated.
Results: Between 2013 and 2014, 285 patients with HCC were treated in the four participating 
centers; of these, 80 were in intermediate stage HCC (Barcelona Clinic Liver Cancer Classifica-
tion [BCLC] B), and 57 were in the advanced stage of the disease (BCLC C). In intermediate 
stage HCC, the most frequent first-line treatment was TACE (63%) followed by sorafenib 
(15%), radiofrequency ablation (14%), and TARE (1.3%). In the advanced stage of HCC, the 
most frequently used first-line therapy was sorafenib (56%), followed by best supportive care 
(21%), TACE (18%), and TARE (3.5%). The total costs of treatment per patient amounted to 
€12,214.54 with sorafenib, €13,418.49 with TACE, and €26,106.08 with TARE. Both in the 
intermediate and in the advanced stage of the disease, variability in treatment patterns among 
centers was observed.
Conclusion: The present analysis raises for the first time the awareness of the overall costs 
incurred by the Italian National Healthcare System for different treatments used in intermediate 
and advanced HCC. Further investigations would be important to better understand the effective 
health care resource usage.
Keywords: disease costs, drugs cost, transarterial embolization, sorafenib
Introduction
Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide, 
which causes approximately 500,000 deaths every year,1 and it is characterized by 
biological and clinical heterogeneity and different prognoses.2,3 It is also the second 
most common cause of death from cancer worldwide and the second most rapidly 
increasing type of cancer in the United States.4–6 The incidence of HCC increases 
progressively with advancing age in all populations, reaching its peak at the age of 
70.7 Moreover, HCC contributes substantially to health care spending.
In Italy, liver cancer is one of the first five causes of death in males (7%);8 12,500 
new cases of liver tumors were expected in 2014, accounting for 3% of the overall 
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incidence of all tumors, with a male:female ratio of 2:1. The 
incidence of HCC has decreased in both sexes, since the 
mid 90s.8 Approximately 21,000 patients with a previous 
diagnosis of HCC (1% of all patients with a cancer) lived 
in Italy in 2011.8
The most important risk factors for HCC are cirrhosis 
due to chronic hepatitis B and chronic hepatitis C, alcoholic 
cirrhosis, or nonalcoholic steatohepatitis, high body mass 
index, and diabetes mellitus.9–11
Worldwide, the most important risk factor for liver 
cancer is chronic hepatitis B or hepatitis C virus. People 
infected with both viruses have a high risk of developing 
chronic hepatitis, cirrhosis, and liver cancer. The risk of 
developing liver cancer is higher if patients are also heavy 
drinkers.12 The vast majority of patients developing liver 
cancer already have some evidence of cirrhosis. Obesity 
increases the risk of developing liver cancer, probably 
because it can result in fatty liver disease and cirrhosis. 
Type 2 diabetes is associated with an increased risk of liver 
cancer, usually in patients who also have other risk factors 
(eg, heavy alcohol use, chronic viral hepatitis).12 This risk 
may be increased as type 2 diabetes patients tend to be over-
weight or obese, which can cause liver problems.12 Although 
HCC patients can benefit from radical resection, transplan-
tation, or radiofrequency ablation thanks to preliminary 
screening and diagnosis, tumors in some patients (those with 
background cirrhosis in particular) still progress rapidly 
because of local spreading or metastases.
The Barcelona Clinic Liver Cancer Classification (BCLC) 
correlates stages of the disease with treatment modalities, and 
identifies five stages of HCC (0, A, B, C, and D) according to 
preestablished prognostic variables and treatment modalities 
for each stage of the disease, thus providing both prognostic 
prediction and treatment allocation recommendations.13 
The American Association for the Study of Liver Disease 
(AASLD) guidelines 2010,14 the European Association for 
the Study of the Liver (EASL) guidelines 2012,15 and the 
Italian Association for the Study of the Liver (AISF 2012)16 
are the most updated guidelines for the treatment of HCC 
and include staging and prognostic–therapeutic stratification 
(EASL–BCLC guidelines) (Figure 1).
In the intermediate stage (BCLC B), patients with asymp-
tomatic tumors (without an invasive pattern) survive 16 months 
on average;2,17,18 chemoembolization prolongs the survival of 
these patients up to 19–20 months, according to randomized 
controlled trial and meta-analysis of pooled data.17
HCC exhibits intense neoangiogenic activity during its 
progression. The rationale for transarterial chemoembolization 
(TACE) is that the intra-arterial infusion of a cytotoxic agent 
followed by embolization of the tumor-feeding blood vessels 
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Figure 1 Updated staging system and treatment strategy.
Notes: Reprinted from the Journal of hepatology, Volume 56, european association for the study of the liver; european Organisation for Research and Treatment of 
Cancer, easl–eORTC clinical prac tice guidelines: management of hepatocellular carcinoma. Pages 908–943. Copyright 2012, with permission from elsevier.15
Abbreviations: hCC, hepatocellular carcinoma; PsT, performance status test; ClT, cadaveric liver transplantation; lDlT, liver donor liver transplantation; RF, radio 
frequency ablation; Pei, percutaneous ethanol injection; TaCe, transarterial chemoembolization; Os, overall survival.
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will result in a strong cytotoxic and ischemic effect. This 
procedure combines transcatheter delivery of chemotherapy 
emulsioned with lipiodol, followed by vascular stagnation 
achieved with embolic agents. Chemoembolization achieves 
partial responses in 15%–55% of patients and significantly 
delays tumor progression and macrovascular invasion. Overall, 
the median survival for intermediate HCC cases is expected to 
be approximately 16 months, whereas after chemoemboliza-
tion, the median survival is ~20 months.15,19,20
Patients in the advanced stage of the disease (BCLC 
stage C) (cancer-related symptoms and/or macrovascular 
invasion and/or extrahepatic spread) have poorer prognosis, 
and the expected median survival without treatment is ~6 
months,18,21 or 25% at first year,19 which is extended to 11 
months by treatment with sorafenib.20
Sorafenib, a multikinase inhibitor, is the standard systemic 
therapy suggested by guidelines for HCC BCLC stage C or for 
intermediate stage after failure of or ineligibility for locore-
gional therapies (treatment-stage migration strategy).13
Efficacy and safety of sorafenib were evaluated in several 
clinical studies;22 the Phase III SHARP study23 demonstrated 
that sorafenib significantly increased overall survival by 44% 
vs placebo (10.7 vs 7.9 months, respectively; P,0.001) and 
almost doubled median time to progression (5.5 vs 2.8 months, 
respectively; hazard ratio [HR]: 0.58, P,0.001).
These results were confirmed by a Phase III study con-
ducted in the Asia–Pacific region;24 in this trial, sorafenib 
significantly increased the overall survival by 47% vs placebo 
(6.5 vs 4.2 months, respectively; HR: 0.68; P=0.014) and 
doubled the median time to progression vs placebo (2.8 vs 
1.4 months, respectively; HR: 0.57, P=0.0005).
In both Phase III studies, the safety profiles of sorafenib 
were predictable and manageable, and the benefits of 
sorafenib were consistent across subgroups by etiology, 
tumor burden, tumor stage, and prior therapy. Based on these 
results, international and national guidelines recommended 
sorafenib as the treatment of choice for advanced HCC (level 
of evidence IA15,25/positively strong). A few studies26–31 
reported the economic burden of HCC worldwide, and while 
sorafenib cost-effectiveness analyses have been published,32,33 
to our knowledge no data exist on the cost-effectiveness of 
TACE for HCC. The objective of the present analysis is to 
investigate treatment pathways and related health care costs 
for HCC BCLC stage B and stage C patients.
Material and methods
The aim of the present survey is to investigate the current 
patterns of treatment, health care resource consumption, and 
costs related to the treatment of HCC in the intermediate and 
advanced stages of the disease, through an analysis of the 
therapeutic pathways followed in four Italian centers. The 
survey was conducted through structured interviews involv-
ing gastroenterology and interventional radiology units. 
Ethical approval for this study was obtained from Policlinico 
Umberto I Roma, AOU Seconda Università di Napoli, Poli-
clinico Paolo Giaccone Palermo, and AO Brotzù Cagliari. 
Informed consent was obtained from all patients.
The data collected in the project remained the property 
of each facility provider and were managed in aggregate and 
anonymous form, without access to individual patient data.
The following information was collected:
•	 Number of patients with HCC by stage
•	 Distribution of patients by treatment options (TACE, tran-
sarterial radioembolization [TARE] systemic treatment) 
and line of treatment (first- and second-line treatment)
•	 Treatments administered (frequency, average number 
of locoregional therapies, and duration of treatment for 
systemic therapies)
•	 Diagnostic procedures and laboratory tests associated 
with each treatment
•	 Specialist visits and follow-up associated with each treat-
ment (percentage of patients undergoing examinations/
visits and frequency)
•	 Consumption of medical and nonmedical supplies associ-
ated with treatments (type of consumables, quantity, and 
unitary costs)
•	 Cost of medical, nursing, and technical staff involved in 
patient management during the treatment.
Unit costs considered in this analysis and related sources 
are reported in Table 1.
As for drugs, the cost per milligram was estimated as 
the average cost of different packs at the maximum price 
reimbursed by the Italian National Health Service.
In order to estimate the average cost per month of therapy, 
an 80% adherence to treatment was considered for sorafenib, 
along with published data on oral antineoplastic treatments.34 
The reference year of the present survey was 2013.
Results
The present survey involved 137 patients with intermediate 
and advanced stage HCC, BCLC stage B, and BCLC stage 
C among a cohort of 285 patients (mean age: 66 years, 
74% males) treated in four Italian centers specialized in 
the treatment of patients with HCC (Policlinico Umberto I 
Roma, AOU Seconda Università di Napoli, Policlinico Paolo 
Giaccone Palermo, AO Brotzù Cagliari). In the overall popu-
lation, 20% of patients were in the very early stage of the 
disease (HCC BCLC stage 0), 17% in the early stage (HCC 
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Table 1 Resources consumption and costs
Item Description Unit cost (€) References
Professional resources interventional radiologist 74.20/h Conferenza stato-Regioni 21/11/2014 – Rapporto sTeM40
hepatologist 74.20/h
anesthetist 74.20/h
nuclear medicine physician 74.20/h
nurse 34.03/h
Radiology technician 34.03/h
hospital pharmacist 61.42/h
Drugs Doxorubicin 0.83/mg italian Medicines agency41
Farmorubicin 1.39/mg
ethiodized oil 2.40/vial
sorafenib 28.70/tablet
Consumables Angiographic sterile field 39.96 selection of public tenders data in 23 relevant italian hospitals; 
prices include VaTangiographic introducer 161.33
Catheter 87.22
Microcatheter 764.25
guide 80.55
Microguide 439.06
DC Beads® 822.60
hemostasis system 17.78
spiral 592.90
Technetium 1,245.95
siR-spheres microspheres 11,000.00
Overheads gastroenterology admission 522.17/day setacci et al42
nuclear medicine admission 600.50/day
angiographic room 7.50/min
BCLC stage A), 28% in the intermediate stage (HCC BCLC 
stage B), 20% in the advanced stage (HCC BCLC stage C), 
and the remaining 15% in the terminal stage (HCC BCLC 
stage D) (Figure 2).
First- and second-line treatments for patients in the inter-
mediate and advanced stages of the disease are reported in 
Figures 3 and 4.
Among the 80 patients in the intermediate stage of the 
disease treated with first-line therapies, 63% (minimum 50% 
to maximum 80%) were treated with TACE, 15% with 
sorafenib (range, 10%–17%), 14% (range, 5%–30%) 
with radiofrequency ablation, and the remaining 10% with 
other therapies (best supportive care, TARE, and liver 
resection).
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Figure 3 First-line treatments of patients with intermediate and advanced hCC.
Abbreviations: TaCe, transarterial chemoembolization; Tae, transarterial embolization; TaRe, transarterial radioembolization; hCC, hepatocellular carcinoma.
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Of these, 55% (n=44) were treated with second-line 
or subsequent therapies. The most frequent second-line or 
subsequent therapies were TACE – 39% (range, 5%-60%) 
and sorafenib – 36% (range, 9%–40%).
Among the 57 patients in the advanced stage of the dis-
ease treated with first-line therapies, sorafenib was the most 
frequently used first-line treatment: 56% (range, 12%–79%). 
Best supportive care was used in 21% of patients (range, 
15%–24%) as the first-line option.
Of these, 54.4% (n=31) were then treated with second-
line or subsequent therapies. TACE was the most frequent 
second-line option in the advanced stage – 45% (range, 
0%–80%), followed by sorafenib – 29% (range, 0%–60%), 
and best supportive care – 26% (range, 0%–30%).
The mean duration of treatment with sorafenib in 137 
patients with intermediate and advanced stage HCC was 
6.1 months in all treatment lines combined.
The average number of TACE was 2.5 procedures/
patient, and patients treated with TARE received an average 
of 1.5 procedures/patient.
The health care resources used in association with each 
type of therapy are reported in Table 2.
Mean resource consumption related to the different treat-
ments, and related costs of consumables and professional 
resources are reported in Tables 3 and 4.
Regarding the systemic treatment, the average cost per 
tablet (200 mg) of sorafenib to public health care structures 
(including the two 5% transient price reductions, as per Italian 
law at the time of the analysis)35,36 accounted for €28.70.
Considering the overall mean daily dosage (612 mg) and an 
estimated 80% of adherence to therapy,34 the average per-month 
cost of treatment with sorafenib amounted to €1,986.36.
On the basis of the unitary cost per procedure/month of 
treatment and the duration of each therapy, the calculated 
average total costs of the different treatments are reported 
in Table 5.
Discussion
The results of the present analysis, aimed at evaluating the 
patterns of treatment and the costs related to HCC treatments, 
Table 2 Resources according to type of treatment
Resource/treatment Sorafenib TACE TARE
specialist visit (hepatologist) × (outpatients) × (outpatients) × (inpatients)
Diagnostic procedures × (outpatients) × (outpatients) × (inpatients)
Prehospitalization workup
hepatic scintigraphy × (inpatients)
Radiopharmaceutical evaluation × (inpatients)
Drug distribution × (outpatients)
Patient preparation × (inpatients) × (inpatients)
Complete angiography × (inpatients) × (inpatients)
Medical device (ie, DC Beads®) or contrast medium (ethiodized oil) injection × (inpatients) × (inpatients)
Chemotherapy drug injection × (outpatients)
Notes: ×, all resource used for each specific treatment.
Abbreviations: TaCe, transarterial chemoembolization; TaRe, transarterial radioembolization.
Table 3 Per-patient resource consumption and costs of consumables by procedure
Consumablesa Unitary costs (€) TACE TARE
Average 
number/patient
Cost/patient/
procedure (€)
Average number/
patient
Cost/patient/
procedure (€)
Angiographic sterile field 39.96 1.00 39.96 1.00 39.96
angiographic introducer 161.33 1.00 161.33 1.10 177.47
Catheter 87.22 1.15 100.31 1.10 95.95
Microcatheter 764.25 1.05 802.46 1.10 840.68
guide wire 80.55 0.74 59.61 1.10 88.61
Microguide wire 439.06 0.57 250.27 – –
DC Beads® 822.60 1.06 871.96 – –
hemostasis system 17.78 0.56 9.96 1.00 17.78
Metal spiral 592.90 – – 10.00 5,929.00
Technetium 1,245.95 – – 0.03 41.54
siR-spheres microspheres 11,000.00 – – 0.50 5,500.00
Total consumables – 2,295.86 – 12,730.99
Note: asorafenib is not included in this table because, as it is an oral treatment, no consumables are necessary to deliver the treatment.
Abbreviations: TaCe, transarterial chemoembolization; TaRe, transarterial radioembolization.
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Table 5 Overall cost per patient by type of treatment
Costs (€) Sorafenib TACE TARE
Total consumables/procedure/patient 2,295.86 12,730.99
Angiographic sterile field – 39.96 39.96
angiographic introducer – 161.33 177.47
Catheter – 100.31 95.95
Microcatheter – 802.46 840.68
guide wire – 59.61 88.61
Microguide wire – 250.27 –
DC Beads® – 871.96 –
hemostasis system – 9.96 17.78
Metal spiral – 5,929.00
Technetium – 41.54
siR-spheres microspheres – 5,500.00
Total drugs/procedure month/patient 1,986.36 68.26 –
ethiodized oil (per procedure) – 1.44 –
Doxorubicin (per procedure) – 42.01 –
Farmorubicin (per procedure) – 24.81 –
sorafenib (month of therapy) 1,986.36 – –
Total professional resources/procedure month/patient 22.61 264.56 320.08
interventional radiologist – 141.11 210.25
hepatologist 12.37 – –
anesthetist – 36.45 –
nuclear medicine physician – – 24.74
Radiology technician – 28.96 –
nuclear medicine technician – – –
nurse – 58.34 85.09
hospital pharmacist 10.24 – –
Overheads/procedure/patient – 2,675.07 4,352.98
Occupation of angiographic rooma – 604.19 750.00
gastroenterology ward admissionb – 2,070.88 –
nuclear medicine admissionb – 3,602.98
Total cost per procedure-month of treatment/patient 2,008.97 5,303.75 17,404.05
average number of treatments 6.08 2.53 1.50
average total cost of treatment/patient 12,214.54 13,418.49 26,106.08
Notes: aaverage occupation of angiographic room per procedure was 80.6 minutes for TaCe and 100 minutes for TaRe. bThe average length of stay in the gastroenterology 
ward was 4 days for TaCe, and the average length of stay in the nuclear medicine ward was 6 days for TaRe.
Abbreviations: TaCe, transarterial chemoembolization; TaRe, transarterial radioembolization.
Table 4 Per-patient resource consumption and costs of professional resources by treatment
Professional resources Hourly 
costs (€)
Sorafenib TACE TARE
Hours/patient/
prescription 
(mean)
Cost/
procedure/
patient (€)
Hours/patient/
prescription 
(mean)
Cost/
procedure/
patient (€)
Hours/patient/
prescription 
(mean)
Cost/
procedure/
patient (€)
interventional radiologist 74.20 – – 1.90 141.11 2.83 210.25
hepatologist 74.20 0.17 12.37 – – – –
anaesthetist 74.20 – – 0.49 36.15 – –
nuclear medicine physician 74.20 – – – – 0.33 24.74
nurse 34.03 – – 1.71 58.34 2.50 85.09
Radiology technician 34.03 – – 0.85 28.96 – –
hospital pharmacist 61.42 0.17 10.24 – – – –
Total professional 
resources
0.34 22.61 4.95 264.56 5.66 320.08
Abbreviations: TaCe, transarterial chemoembolization; TaRe, transarterial radioembolization.
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show a high variability among centers concerning procedures 
used in both the intermediate and advanced stages, first-line 
and subsequent lines. TACE was the treatment of choice in 
intermediate HCC, as suggested by the guidelines, but ~38% 
of patients were treated with alternative therapies. Sorafenib 
was the most frequently used first-line therapy in advanced 
HCC as recommended by international and Italian guidelines, 
although ~45% of these patients received other first-line 
treatments. A potential role of the combined approach of 
these therapies in intermediate HCC patients, as suggested by 
recent publications,37 is still experimental and needs further 
confirmatory trials. The cost of HCC treatment amounted to 
~€12,200/patient for sorafenib, €13,400/patient for TACE, 
and €26,100/patient for TARE.
The unitary costs of the treatments that were used in the 
calculations originate from tariffs and average acquisition 
costs at the national level (determined on a benchmark of 
23 tenders). This methodology allows a comparison among 
treatment strategies based on the same evaluation criteria. 
From the perspective of health care cost of treatment, some 
facts should be taken into consideration. Treatment guide-
lines recommend TACE for intermediate HCC. The costs 
sustained by the centers for this procedure are, however, only 
partially covered by their diagnosis-related group’s (DRG)38 
tariff (€5,304 vs a reimbursement tariff of €4,085; DRG 203: 
malignancy of hepatobiliary system or pancreas).32 Regarding 
TARE, which is not recommended by treatment guidelines 
either in intermediate stage or in advanced stage HCC, 
the costs sustained by the centers are relevant (~€17,400/
patient/procedure), while at the national level, the DRG’s 
reimbursement tariff for TARE is DRG 409 (radiotherapy),38 
reimbursed at €1,471. Among the centers involved in the 
present study, only one performs this kind of procedure.
Sorafenib, recommended by national and international 
guidelines as the treatment of choice for advanced HCC, is 
dispensed in Italy by hospital pharmacies and registered in 
the “file F” that is used for specific categories of drugs dis-
tributed by NHS health care structures not covered by DRGs 
or tariffs (sorafenib cost is directly reimbursed to hospitals 
by local health care units or regions). We note, however, 
that this evaluation is only a cost analysis and does not take 
into account unplanned hospitalization, cost of side effects, 
and their treatment. The inclusion of these “shadow costs” 
could change the final cost of HCC treatment. Furthermore, 
we did not find any cases of HCC surgical treatments. Recent 
literature,39 for example, showed that surgical therapies could 
also give the best results in patients with intermediate or 
advanced HCC. A limitation of the present study is that the 
centers that participated in this analysis may not accurately 
mirror the situation of the entire Italian territory, although 
they are centers experienced in the treatment of HCC, 
selected among hospitals with a wide volume of activity 
in this field. To our knowledge, this is the first study that 
evaluates the costs of treatment patterns for intermediate/
advanced HCC patients in a real-life setting in Italy.
Conclusion
Sorafenib is recommended by international and Italian guide-
lines (level of evidence IA/strong positive) as the treatment 
of choice for advanced HCC. It was the most frequently used 
treatment in this setting; the associated cost of treatment was 
€12,200/patient. TACE was the most widely used treatment in 
intermediate HCC, and its associated costs of €13,400/patient 
are only partially covered by the DRG’s reimbursement 
tariffs. TARE, which is not indicated as a treatment choice 
in HCC management guidelines, was performed in one of 
the participating centers with an associated average cost of 
€26,100/patient that is not covered by the national reference 
DRG. The present study highlights the need for additional 
analyses of the national health care system resources that are 
being used routinely for the treatment of HCC and the associ-
ated outcomes, and can be the basis for future research and 
analysis of the cost-effectiveness of TACE, alone or combined 
with sorafenib, for the treatment of HCC.
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